Hematopoietic Cell Transplantation Clinical Trial
Official title:
Prospective Multi Center Study of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS)
This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | February 5, 2026 |
Est. primary completion date | February 5, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Years to 26 Years |
Eligibility | Inclusion Criteria: - Children, adolescents and young adults (AYA) 0-26 years of age undergoing HSCT. - Recipients of autologous and allogeneic HSCT. - Any preparative regimen. Exclusion Criteria: - Any patient who does not consent/assent to participation. - Any patient for whom 5 mL blood sample(s) drawn at specified intervals would pose any more than minimal risk, as defined by institutional guidelines and at discretion of treating physician will be ineligible for biorepository banking. |
Country | Name | City | State |
---|---|---|---|
United States | Duke University | Durham | North Carolina |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Duke University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of pediatric patients undergoing hematopoietic cell transplant (HCT) who develop endotheliopathies (SOS, TMA, DAH and IPS) and/or MODS within 100 days of such therapies. | through study completion, an average of 1 year | ||
Primary | Proportion of pediatric patients undergoing (HCT) who experience abnormal levels of circulating angiogenic factors within 100 days post HCT-CT in the setting of endotheliopathies. | through study completion, an average of 1 year | ||
Primary | Proportion of pediatric patients undergoing (HCT) who experience abnormal levels of vascular permeability within 100 days post HCT-CT in the setting of endotheliopathies. | through study completion, an average of 1 year | ||
Primary | Proportion of pediatric patients undergoing (HCT) who experience abnormal levels of inflammatory factors within 100 days post HCT-CT in the setting of endotheliopathies. | through study completion, an average of 1 year | ||
Secondary | Overall survival. | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03179761 -
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT05634512 -
Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
|
||
Completed |
NCT05600101 -
Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT05866302 -
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
|
||
Completed |
NCT04139577 -
FMT In High-Risk Acute GVHD After ALLO HCT
|
Phase 1 | |
Completed |
NCT04727827 -
Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation
|
N/A |